Cardiff Oncology (CRDF) Scheduled to Post Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) will be posting its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Cardiff Oncology to post earnings of ($0.25) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.05. Cardiff Oncology had a negative return on equity of 50.13% and a negative net margin of 8,492.01%. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.08 million. On average, analysts expect Cardiff Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cardiff Oncology Stock Down 2.1 %

NASDAQ:CRDF traded down $0.09 during mid-day trading on Wednesday, hitting $4.27. 104,478 shares of the company traded hands, compared to its average volume of 1,435,453. The stock’s fifty day moving average price is $4.42 and its 200-day moving average price is $2.45. Cardiff Oncology has a one year low of $0.94 and a one year high of $6.42. The firm has a market cap of $190.91 million, a price-to-earnings ratio of -4.59 and a beta of 1.94.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CRDF. Piper Sandler upped their price objective on Cardiff Oncology from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st. HC Wainwright upped their price objective on Cardiff Oncology from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.